Correction of: Nuevolution AB (publ) announces timing for the fourth quarter release and webcast

Stockholm, 30 August 2017 – In the press release announcing the timing for the fourth quarter release and webcast announced at 11:00 CEST, the correct text should be: Nuevolution AB (publ) (NUE.ST) announces today that it will report its fourth quarter 2016/17 (corrected from 2015/16) financial results on Wednesday 6 September 2017 at 8:30 CEST.

For more information, please contact:

Alex Haahr Gouliaev, CEO
Phone: +45 3913 0902
Email: ahg@nuevolution.com

Henrik Damkjær Simonsen, CFO
Phone: +45 3913 0947
Email: hs@nuevolution.com

 

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was sent for publication on Wednesday 30 August 2017 at 13:30 CEST.

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden (ticker: NUE). Redeye AB acts as Certified Advisor to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com